CA3122840A1 - Crystalline forms and salt forms of a kinase inhibitor - Google Patents

Crystalline forms and salt forms of a kinase inhibitor Download PDF

Info

Publication number
CA3122840A1
CA3122840A1 CA3122840A CA3122840A CA3122840A1 CA 3122840 A1 CA3122840 A1 CA 3122840A1 CA 3122840 A CA3122840 A CA 3122840A CA 3122840 A CA3122840 A CA 3122840A CA 3122840 A1 CA3122840 A1 CA 3122840A1
Authority
CA
Canada
Prior art keywords
compound
peaks
xrpd pattern
theta scale
crystalline solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3122840A
Other languages
English (en)
French (fr)
Inventor
Frenel Demorin
Khalid Shah
Sagar Shakya
Peter Wong
Courtney S. Johnson
Melanie Janelle Bevill
Stephan D. Parent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CA3122840A1 publication Critical patent/CA3122840A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3122840A 2018-12-13 2019-12-12 Crystalline forms and salt forms of a kinase inhibitor Pending CA3122840A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779430P 2018-12-13 2018-12-13
US62/779,430 2018-12-13
US201962856469P 2019-06-03 2019-06-03
US62/856,469 2019-06-03
PCT/US2019/065972 WO2020123800A1 (en) 2018-12-13 2019-12-12 Crystalline forms and salt forms of a kinase inhibitor

Publications (1)

Publication Number Publication Date
CA3122840A1 true CA3122840A1 (en) 2020-06-18

Family

ID=69160358

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3122840A Pending CA3122840A1 (en) 2018-12-13 2019-12-12 Crystalline forms and salt forms of a kinase inhibitor

Country Status (33)

Country Link
US (2) US12017995B2 (cg-RX-API-DMAC7.html)
EP (2) EP4631505A3 (cg-RX-API-DMAC7.html)
JP (3) JP7509779B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250103803A (cg-RX-API-DMAC7.html)
CN (1) CN113329790A (cg-RX-API-DMAC7.html)
AU (2) AU2019395419B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011333A2 (cg-RX-API-DMAC7.html)
CA (1) CA3122840A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001537A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007613A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210375A (cg-RX-API-DMAC7.html)
DK (1) DK3894012T3 (cg-RX-API-DMAC7.html)
ES (1) ES3052838T3 (cg-RX-API-DMAC7.html)
FI (1) FI3894012T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20247596B (cg-RX-API-DMAC7.html)
HR (1) HRP20251122T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072868T2 (cg-RX-API-DMAC7.html)
IL (2) IL283860B2 (cg-RX-API-DMAC7.html)
LT (1) LT3894012T (cg-RX-API-DMAC7.html)
MA (1) MA54458B1 (cg-RX-API-DMAC7.html)
MD (1) MD3894012T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006951A (cg-RX-API-DMAC7.html)
PE (1) PE20211757A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551356A1 (cg-RX-API-DMAC7.html)
PL (1) PL3894012T4 (cg-RX-API-DMAC7.html)
PT (1) PT3894012T (cg-RX-API-DMAC7.html)
RS (1) RS67216B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105949RA (cg-RX-API-DMAC7.html)
SI (1) SI3894012T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500346T1 (cg-RX-API-DMAC7.html)
TW (2) TWI913821B (cg-RX-API-DMAC7.html)
WO (1) WO2020123800A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103844B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
KR102826380B1 (ko) * 2019-06-03 2025-06-26 엑셀리시스, 인코포레이티드 카이네이스 저해제의 결정질 염 형태
FI4143169T3 (fi) * 2020-04-30 2026-06-08 Exelixis Inc Kinaasi-inhibiittorin valmistusmenetelmät
PH12023550160A1 (en) 2020-07-31 2023-09-18 Exelixis Inc Combinations for the Treatment of Cancer
IL302485A (en) * 2020-11-05 2023-06-01 Exelixis Inc Kinase inhibitor pharmaceutical preparations
CN112650176B (zh) * 2020-12-22 2022-08-30 天能化工有限公司 一种盐酸解析开停车工序的dcs控制方法
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
AU2022420610A1 (en) 2021-12-22 2024-06-27 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
CN116751161A (zh) * 2023-06-28 2023-09-15 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
JP4667537B2 (ja) 2008-04-10 2011-04-13 大鵬薬品工業株式会社 アシルチオウレア化合物又はその塩、及びその用途
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
EA032757B1 (ru) 2014-02-14 2019-07-31 Экселиксис, Инк. Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
MX2019012505A (es) 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
HRP20251184T1 (hr) 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
KR102826380B1 (ko) * 2019-06-03 2025-06-26 엑셀리시스, 인코포레이티드 카이네이스 저해제의 결정질 염 형태

Also Published As

Publication number Publication date
JP2024038167A (ja) 2024-03-19
IL283860B2 (en) 2025-10-01
IL320433A (en) 2025-06-01
US20230029213A1 (en) 2023-01-26
HRP20251122T1 (hr) 2025-11-21
LT3894012T (lt) 2025-10-10
MX2021006951A (es) 2021-07-15
IL283860A (en) 2021-07-29
EP4631505A2 (en) 2025-10-15
AU2019395419A1 (en) 2021-07-01
CN113329790A (zh) 2021-08-31
JP7509779B2 (ja) 2024-07-02
GEP20247596B (en) 2024-02-26
PL3894012T3 (pl) 2026-01-05
KR20250103803A (ko) 2025-07-07
JP2026031599A (ja) 2026-02-24
EP4631505A3 (en) 2025-12-10
ZA202103844B (en) 2024-11-27
JP7783870B2 (ja) 2025-12-10
TW202039440A (zh) 2020-11-01
WO2020123800A1 (en) 2020-06-18
JP2022512399A (ja) 2022-02-03
KR20210102381A (ko) 2021-08-19
PL3894012T4 (pl) 2026-01-05
HUE072868T2 (hu) 2025-12-28
PH12021551356A1 (en) 2021-12-06
CO2021007613A2 (es) 2021-06-21
MA54458B1 (fr) 2025-09-30
RS67216B1 (sr) 2025-10-31
CL2021001537A1 (es) 2022-02-04
ES3052838T3 (en) 2026-01-15
SI3894012T1 (sl) 2025-10-30
AU2025234277A1 (en) 2025-10-16
MA54458A (fr) 2021-10-20
SG11202105949RA (en) 2021-07-29
TWI913821B (zh) 2026-02-01
KR102828472B1 (ko) 2025-07-03
DK3894012T3 (da) 2025-09-15
PE20211757A1 (es) 2021-09-07
TWI852963B (zh) 2024-08-21
AU2019395419B2 (en) 2025-06-26
BR112021011333A2 (pt) 2021-08-31
MD3894012T2 (ro) 2025-11-30
US12679809B2 (en) 2026-07-14
EP3894012B1 (en) 2025-06-18
EP3894012A1 (en) 2021-10-20
TW202519513A (zh) 2025-05-16
SMT202500346T1 (it) 2025-11-10
CR20210375A (es) 2021-08-18
PT3894012T (pt) 2025-09-25
FI3894012T3 (fi) 2025-09-18
US12017995B2 (en) 2024-06-25
US20240300897A1 (en) 2024-09-12
IL283860B1 (en) 2025-06-01

Similar Documents

Publication Publication Date Title
US20240300897A1 (en) Crystalline forms and salt forms of a kinase inhibitor
AU2019449809B2 (en) Crystalline salt forms of a kinase inhibitor
US20250368606A1 (en) Crystalline forms and salt forms of a kinase inhibitor
HK40061293A (en) Crystalline forms and salt forms of a kinase inhibitor
HK40061293B (en) Crystalline forms and salt forms of a kinase inhibitor
OA20944A (en) Crystalline salt forms of a kinase inhibitor
EA048718B1 (ru) Кристаллические солевые формы ингибитора киназы
BR122025022768A2 (pt) Formas cristalinas, sais de ácido clorídrico e ácido fosfórico cristalinos, composição farmacêutica e usos relacionados
HK40067664B (en) Crystalline salt forms of a kinase inhibitor
HK40067664A (en) Crystalline salt forms of a kinase inhibitor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231211

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241122

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241122

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250411

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250414

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250718

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250718

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251126

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251126

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20260116

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260204

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260210

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260210

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260210

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20260227

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260305

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260311

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260311

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260601

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260601